Axcella Health’s (NASDAQ:AXLA) lock-up period is set to end on Tuesday, November 5th. Axcella Health had issued 3,571,428 shares in its IPO on May 9th. The total size of the offering was $71,428,560 based on an initial share price of $20.00. After the end of the company’s lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.
AXLA has been the topic of several research analyst reports. Zacks Investment Research downgraded shares of Axcella Health from a “hold” rating to a “sell” rating in a report on Friday, October 18th. ValuEngine raised shares of Axcella Health from a “hold” rating to a “buy” rating in a report on Friday, October 4th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. Axcella Health presently has an average rating of “Buy” and a consensus price target of $22.00.
Axcella Health stock opened at $5.00 on Tuesday. The company’s fifty day simple moving average is $5.77. The company has a current ratio of 17.42, a quick ratio of 17.42 and a debt-to-equity ratio of 0.27. Axcella Health has a 52-week low of $4.79 and a 52-week high of $15.99.
Axcella Health (NASDAQ:AXLA) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.64) by ($0.31). On average, equities research analysts predict that Axcella Health will post -3.82 earnings per share for the current fiscal year.
In other Axcella Health news, Director David R. Epstein purchased 6,941 shares of the firm’s stock in a transaction that occurred on Friday, August 2nd. The shares were bought at an average price of $7.00 per share, with a total value of $48,587.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
A number of institutional investors have recently added to or reduced their stakes in AXLA. Harbourvest Partners LLC purchased a new stake in Axcella Health during the second quarter valued at $11,442,000. Artal Group S.A. purchased a new stake in Axcella Health during the second quarter valued at $3,628,000. BlackRock Inc. purchased a new stake in Axcella Health during the second quarter valued at $667,000. Vanguard Group Inc. purchased a new stake in Axcella Health during the second quarter valued at $499,000. Finally, Tower Research Capital LLC TRC purchased a new stake in Axcella Health during the second quarter valued at $122,000. 62.26% of the stock is currently owned by institutional investors.
Axcella Health Company Profile
There is no company description available for Axcella Health Inc
Read More: How Do Mutual Funds Work?
Receive News & Ratings for Axcella Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axcella Health and related companies with MarketBeat.com's FREE daily email newsletter.